{"id":65214,"date":"2026-05-13T23:00:21","date_gmt":"2026-05-13T15:00:21","guid":{"rendered":"https:\/\/flcube.com\/?p=65214"},"modified":"2026-05-13T23:00:23","modified_gmt":"2026-05-13T15:00:23","slug":"serviers-b7-h4-adc-emiltatug-ledadotin-receives-fda-breakthrough-therapy-designation-for-advanced-adenoid-cystic-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65214","title":{"rendered":"Servier&#8217;s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma"},"content":{"rendered":"\n<p><strong>Servier<\/strong> announced on May 12, 2026, that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> to its <strong>Emiltatug Ledadotin (Emi-Le)<\/strong> for the treatment of patients with <strong>locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC)<\/strong> with solid histology or high-grade transformation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-development-milestone\">Regulatory &amp; Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Servier<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Emiltatug Ledadotin (Emi-Le)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>B7-H4-directed antibody-drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Locally advanced, recurrent or metastatic ACC with solid histology\/high-grade transformation<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>FDA Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>May 12, 2026<\/td><\/tr><tr><td><strong>Current Trial Phase<\/strong><\/td><td>Phase 1 (multicenter)<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>No currently approved treatments available<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-adc-technology-innovation\">ADC Technology Innovation<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-precision-engineering-features\">Precision Engineering Features<\/h3>\n\n\n\n<p>Emi-Le represents a <strong>next-generation ADC platform<\/strong> with multiple proprietary innovations:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><th>Therapeutic Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>B7-H4 (VTCN1)<\/td><td>Tumor-selective antigen overexpressed in multiple solid tumors<\/td><\/tr><tr><td><strong>Drug-to-Antibody Ratio (DAR)<\/strong><\/td><td>Precise DAR 6<\/td><td>Optimized payload delivery with enhanced therapeutic index<\/td><\/tr><tr><td><strong>Payload<\/strong><\/td><td>Proprietary auristatin-F HPA<\/td><td>Potent microtubule-disrupting agent with controlled activity<\/td><\/tr><tr><td><strong>Bystander Effect<\/strong><\/td><td>Controlled design<\/td><td>Enables killing of neighboring tumor cells while minimizing off-target toxicity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-rationale-for-acc\">Clinical Rationale for ACC<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet medical need<\/strong>: ACC is a <strong>rare salivary gland cancer<\/strong> with <strong>no approved therapies<\/strong> for advanced\/metastatic disease<\/li>\n\n\n\n<li><strong>Aggressive subtypes<\/strong>: Solid histology and high-grade transformation associated with poor prognosis and rapid progression<\/li>\n\n\n\n<li><strong>Target validation<\/strong>: B7-H4 expression confirmed in ACC tumor samples, providing strong biological rationale<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-program\">Clinical Development Program<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-phase-1-trial-design\">Phase 1 Trial Design<\/h3>\n\n\n\n<p>The ongoing <strong>multicenter Phase 1 study<\/strong> is evaluating Emi-Le across multiple solid tumor types:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Tumor Type<\/th><th>Rationale<\/th><th>Development Priority<\/th><\/tr><\/thead><tbody><tr><td><strong>Adenoid Cystic Carcinoma (ACC)<\/strong><\/td><td>High unmet need, B7-H4 expression<\/td><td>Primary focus (BTD indication)<\/td><\/tr><tr><td><strong>Breast cancer<\/strong><\/td><td>B7-H4 overexpression in triple-negative subtypes<\/td><td>Secondary indication<\/td><\/tr><tr><td><strong>Endometrial cancer<\/strong><\/td><td>Frequent B7-H4 expression in aggressive variants<\/td><td>Expansion cohort<\/td><\/tr><tr><td><strong>Ovarian cancer<\/strong><\/td><td>Established B7-H4 target validation<\/td><td>Exploratory arm<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-initial-clinical-data\">Initial Clinical Data<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safety profile<\/strong>: <strong>Manageable side effects<\/strong> observed in initial Phase 1 cohorts<\/li>\n\n\n\n<li><strong>Efficacy signals<\/strong>: <strong>Confirmed objective responses<\/strong> demonstrated across multiple tumor types<\/li>\n\n\n\n<li><strong>Therapeutic window<\/strong>: Controlled bystander effect contributing to favorable tolerability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-market-context\">Strategic Implications &amp; Market Context<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-servier\">For Servier<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology leadership<\/strong>: Establishes Servier as innovator in next-generation ADC development<\/li>\n\n\n\n<li><strong>Rare disease focus<\/strong>: Addresses significant unmet need in orphan oncology indication<\/li>\n\n\n\n<li><strong>Platform validation<\/strong>: Success validates B7-H4 targeting approach for broader solid tumor applications<\/li>\n\n\n\n<li><strong>Regulatory acceleration<\/strong>: BTD provides intensive FDA guidance and potential priority review<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC market evolution<\/strong>: Next-generation ADCs focusing on <strong>novel targets<\/strong>, <strong>optimized DAR<\/strong>, and <strong>controlled bystander effects<\/strong><\/li>\n\n\n\n<li><strong>B7-H4 emerging target<\/strong>: Multiple companies developing B7-H4 therapeutics, but Emi-Le represents advanced clinical validation<\/li>\n\n\n\n<li><strong>Rare cancer opportunity<\/strong>: Orphan drug designation potential provides market exclusivity and development incentives<\/li>\n\n\n\n<li><strong>Treatment paradigm shift<\/strong>: First potential disease-modifying therapy for advanced ACC<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-assessment\">Market Opportunity Assessment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ACC prevalence<\/strong>: Estimated <strong>1,200-1,500 new cases annually<\/strong> in the U.S., with significant proportion progressing to advanced disease<\/li>\n\n\n\n<li><strong>Pricing premium<\/strong>: Orphan oncology indications typically command premium pricing ($150,000-$300,000 annually)<\/li>\n\n\n\n<li><strong>Global expansion<\/strong>: Potential for similar regulatory designations in EU and other major markets<\/li>\n\n\n\n<li><strong>Combination potential<\/strong>: Future studies may explore combinations with immunotherapy or targeted agents<\/li>\n<\/ul>\n\n\n\n<p>The BTD represents a <strong>significant de-risking milestone<\/strong> for Emi-Le, validating both the novel B7-H4 target and Servier&#8217;s precision ADC engineering approach in one of oncology&#8217;s most challenging rare cancers.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for Emi-Le. Actual results may differ due to risks including clinical trial outcomes, safety profile, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,34],"class_list":["post-65214","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-breakthrough-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Servier&#039;s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Emiltatug Ledadotin (Emi-Le) for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC) with solid histology or high-grade transformation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65214\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Servier&#039;s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma\" \/>\n<meta property=\"og:description\" content=\"Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Emiltatug Ledadotin (Emi-Le) for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC) with solid histology or high-grade transformation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65214\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T15:00:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T15:00:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65214#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65214\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Servier&#8217;s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma\",\"datePublished\":\"2026-05-13T15:00:21+00:00\",\"dateModified\":\"2026-05-13T15:00:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65214\"},\"wordCount\":568,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Breakthrough therapy\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65214#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65214\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65214\",\"name\":\"Servier's B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-13T15:00:21+00:00\",\"dateModified\":\"2026-05-13T15:00:23+00:00\",\"description\":\"Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Emiltatug Ledadotin (Emi-Le) for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC) with solid histology or high-grade transformation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65214#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65214\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65214#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Servier&#8217;s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Servier's B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Emiltatug Ledadotin (Emi-Le) for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC) with solid histology or high-grade transformation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65214","og_locale":"en_US","og_type":"article","og_title":"Servier's B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma","og_description":"Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Emiltatug Ledadotin (Emi-Le) for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC) with solid histology or high-grade transformation.","og_url":"https:\/\/flcube.com\/?p=65214","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T15:00:21+00:00","article_modified_time":"2026-05-13T15:00:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65214#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65214"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Servier&#8217;s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma","datePublished":"2026-05-13T15:00:21+00:00","dateModified":"2026-05-13T15:00:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65214"},"wordCount":568,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Breakthrough therapy"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65214#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65214","url":"https:\/\/flcube.com\/?p=65214","name":"Servier's B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-13T15:00:21+00:00","dateModified":"2026-05-13T15:00:23+00:00","description":"Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Emiltatug Ledadotin (Emi-Le) for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC) with solid histology or high-grade transformation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65214#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65214"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65214#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Servier&#8217;s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65214"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65214\/revisions"}],"predecessor-version":[{"id":65215,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65214\/revisions\/65215"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}